Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome

European Urology

Volumn 58, Issue 1, 2010, Pages 112-117

  Tilki, Derya ^a,b   Reich, Oliver ^a   Karakiewicz, Pierre I ^c   Novara, Giacomo ^d   Kassouf, Wassim ^e   Ergün, Süleyman ^f   Fradet, Yves ^g   Ficarra, Vincenzo ^d   Sonpavde, Guru ^h   Stief, Christian G ^a   Skinner, Eila ⁱ   Svatek, Robert S ^j   Lotan, Yair ^j   Sagalowsky, Arthur I ^j   Shariat, Shahrokh F ^k  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF PADOVA   (Italy)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITÉ LAVAL   (Canada)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

AJCC stage; Prognosis; Substaging; Survival; Urinary bladder; Urothelial carcinoma

Indexed keywords

AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CYSTECTOMY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PATIENT CODING; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; VALIDATION STUDY;

AGED; CARCINOMA; CYSTECTOMY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 77952883914     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.01.015     Document Type: Article

References (19)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
3. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
4. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51 (2007) 137-151 discussion 149-51
5. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176 (2006) 2414-2422 discussion 2422
6. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 21 (2003) 690-696
7. Hautmann R.E., Gschwend J.E., de Petriconi R.C., Kron M., and Volkmer B.G. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176 (2006) 486-492 discussion 491-2
8. Dalbagni G., Genega E., Hashibe M., et al. Cystectomy for bladder cancer: a contemporary series. J Urol 165 (2001) 1111-1116
9. Fleming I.D., Cooper J.S., Hensen D.E., et al. AJCC cancer staging manual. 5th ed. (1997), Lippincott-Raven, Philadelphia, PA p. 241-3
10. Boudreaux Jr. K.J., Clark P.E., Lowrance W.T., et al. Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 181 (2009) 540-545 discussion 546
11. Cheng L., Neumann R.M., Scherer B.G., et al. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer 85 (1999) 2638-2647
12. Girgin C., Sezer A., Delibas M., Sahin O., Oder M., and Dincel C. Impact of the level of muscle invasion in organ-confined bladder cancer. Urol Int 78 (2007) 145-149
13. Herranz Amo F., Verdu Tartajo F., Diez Cordero J.M., et al. Differences in survival of patients with bladder cancer depending on depth of muscle infiltration [in Spanish]. Actas Urol Esp 25 (2001) 110-114
14. Tokgoz H., Turkolmez K., Resorlu B., Kose K., Tulunay O., and Beduk Y. Pathological staging of muscle invasive bladder cancer. Is substaging of pT2 tumors really necessary?. Int Braz J Urol 33 (2007) 777-783 discussion 783-4
15. Yu R.J., Stein J.P., Cai J., Miranda G., Groshen S., and Skinner D.G. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 176 (2006) 493-498 discussion 498-9
16. Jewett H.J. Carcinoma of the bladder: influence of depth of infiltration on the 5-year results following complete extirpation of the primary growth. J Urol 67 (1952) 672-680
17. Ghoneim M.A., Abdel-Latif M., el-Mekresh M., et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 180 (2008) 121-127
18. Quek M.L., Stein J.P., Nichols P.W., et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174 (2005) 103-106
19. Lotan Y., Gupta A., Shariat S.F., et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23 (2005) 6533-6539